Tharimmune (THAR) shares were nearly 35% higher pre-bell Thursday, extending Wednesday's rally.
Evoke Pharma (EVOK) stock was up 30% after the company said its US patent for its gastroparesis nasal spray has been listed in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations.
Cato (CATO) shares were up 14% after the company reported higher fiscal Q2 earnings and revenue year over year.
Fundamental Global (FGNX) stock was up 9.2%, following a 0.1% gain in the previous session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.